Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00:01 2023-02-07 pm EST
163.40 USD   +0.02%
07:10aThird Circuit Dismisses J&J Bankruptcy Case For Lack Of Good Faith
AQ
03:09aPut Down Your Fiddle : Third Circuit Halts Johnson & Johnson's Texas Two-step
AQ
02/06Johnson & Johnson's Janssen Unit Says Phase 2 Trial of Blood Disorder Drug Nipocalimab Meets Primary Endpoint
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Morgan Stanley Adjusts Price Target on Johnson & Johnson to $178 From $170, Maintains Equalweight Rating

12/01/2022 | 09:23am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 0.02% 163.4 Delayed Quote.-6.82%
MORGAN STANLEY 0.32% 99.22 Delayed Quote.16.95%
All news about JOHNSON & JOHNSON
07:10aThird Circuit Dismisses J&J Bankruptcy Case For Lack Of Good Faith
AQ
03:09aPut Down Your Fiddle : Third Circuit Halts Johnson & Johnson's Texas Two-step
AQ
02/06Johnson & Johnson's Janssen Unit Says Phase 2 Trial of Blood Disorder Drug Nipocalimab ..
MT
02/06Johnson & Johnson to Participate in the Cowen 43rd Annual HealthCare Conference
AQ
02/06Janssen Reports Positive Topline Phase 2 Results for Nipocalimab in Pregnant Individual..
CI
02/06Addex's Partner Janssen Concludes Patient Recruitment In First Part Of Mid-stage Epilep..
MT
02/02Johnson & Johnson to Participate in the Cowen 43rd Annual HealthCare Conference
BU
02/02Avalon GloboCare Partnerships, Completed Capital Raise, And Robust IP Portfolio Expose ..
AQ
02/02Formycon Licenses Stelara Biosimilar Candidate to Fresenius Unit
MT
01/31Moody's Says Johnson & Johnson's Court Loss is Negative Credit Development
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 017 M - -
Net income 2022 20 668 M - -
Net cash 2022 10 806 M - -
P/E ratio 2022 20,6x
Yield 2022 2,70%
Capitalization 427 B 427 B -
EV / Sales 2022 4,38x
EV / Sales 2023 4,15x
Nbr of Employees 141 700
Free-Float 83,8%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 163,40 $
Average target price 180,90 $
Spread / Average Target 10,7%
EPS Revisions
Managers and Directors
Joaquin Duato Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
James D. Swanson Global Chief Information Officer & Executive VP
Dan Zelem Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-6.82%427 102
ELI LILLY AND COMPANY-7.31%320 837
NOVO NORDISK A/S2.13%311 923
ROCHE HOLDING AG-2.27%269 272
MERCK & CO., INC.-6.24%263 757
ABBVIE INC.-10.27%256 378